Abstract
The formation of senile plaques containing amyloid β peptides (Aβ peptides) as a major constituent plays a significant role in development of Alzheimers disease. The concentration of Aβ peptides in the brain is determined by a combination of their rate of synthesis and their rate of clearance. Considerable effort has been expended in producing inhibitors of the β and γ secretases involved in the synthesis of the Aβ peptides. More recently interest in the mechanism of clearance of the Aβ peptides has emerged, as promoting Aβ peptide clearance represents an alternative therapeutic approach. It now appears that cleavage of Aβ peptide by peptidases and proteases represents the major mechanism of clearance. This review describes those peptidases and proteases implicated in Aβ peptide clearance, the evidence that these enzymes function in vivo, and how they may represent new therapeutic targets.
Keywords: amyloid beta-peptide, ab, a betapeptides, b secretase, r secretase
Current Pharmaceutical Design
Title: Peptidases, Proteases and Amyloid β-Peptide Catabolism
Volume: 9 Issue: 6
Author(s): Louis B. Hersh
Affiliation:
Keywords: amyloid beta-peptide, ab, a betapeptides, b secretase, r secretase
Abstract: The formation of senile plaques containing amyloid β peptides (Aβ peptides) as a major constituent plays a significant role in development of Alzheimers disease. The concentration of Aβ peptides in the brain is determined by a combination of their rate of synthesis and their rate of clearance. Considerable effort has been expended in producing inhibitors of the β and γ secretases involved in the synthesis of the Aβ peptides. More recently interest in the mechanism of clearance of the Aβ peptides has emerged, as promoting Aβ peptide clearance represents an alternative therapeutic approach. It now appears that cleavage of Aβ peptide by peptidases and proteases represents the major mechanism of clearance. This review describes those peptidases and proteases implicated in Aβ peptide clearance, the evidence that these enzymes function in vivo, and how they may represent new therapeutic targets.
Export Options
About this article
Cite this article as:
Hersh B. Louis, Peptidases, Proteases and Amyloid β-Peptide Catabolism, Current Pharmaceutical Design 2003; 9 (6) . https://dx.doi.org/10.2174/1381612033391676
DOI https://dx.doi.org/10.2174/1381612033391676 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diabetic Bone Fracture Repair: A Progenitor Cell-Based Paradigm
Current Stem Cell Research & Therapy Gestational Exposure to Serotonin Reuptake Inhibitors and Pregnancy Outcome; Exploring the Role of Bias and Confounders
Current Neuropharmacology Phenothiazine: The Parent Molecule
Current Drug Targets Immune Abnormalities and Endotoxemia in Patients with Ulcerative Colitis and in Their First Degree Relatives: Attempts at Neutralizing Endotoxin- Mediated Effects
Current Pharmaceutical Design Editorial (Thematic Issue: New Behaviors, New Drugs: The Modern Landscape of Addiction)
Current Pharmaceutical Design FDA-approved Drugs Selected Using Virtual Screening Bind Specifically to G-quadruplex DNA
Current Pharmaceutical Design Interactions of VIP, Secretin and PACAP1-38 with Phospholipids: A Biological Paradox Revisited
Current Pharmaceutical Design Editorial [Hot Topic: Hepatocyte Growth Factor and Its Signalling, New Horizons in Medicine and Therapies (Guest Editors: Wen G. Jiang and Kunio Matsumoto)]
Current Signal Transduction Therapy Genetic Factors in Parkinsons Disease and Potential Therapeutic Targets
Current Neuropharmacology Genetically Modified Mice as Tools to Understand the Neurobiological Substrates of Depression
Current Pharmaceutical Design Lysosomal Molecules are Up-Regulated in the Articular Cartilage Explants Subjected to Oxidative Stress and in the Cartilage from an Osteoarthritis-Induced Rat Model
Recent Patents on Biomarkers Molecular Insight into the Crosstalk of UPS Components and Alzheimer’s Disease
Current Protein & Peptide Science Cannabinoids: Novel Medicines for the Treatment of Huntingtons Disease
Recent Patents on CNS Drug Discovery (Discontinued) Hypoxia-Inducible Factor-1α Contributes to Brain Edema after Stroke by Regulating Aquaporins and Glycerol Distribution in Brain
Current Neurovascular Research Metal Nanocomposites Based Electrochemical Sensor Platform for Few Emerging Biomarkers
Current Analytical Chemistry Indazole Derivatives: Promising Anti-tumor Agents
Anti-Cancer Agents in Medicinal Chemistry Risks Associated with Vortioxetine in the Established Therapeutic Indication
Current Neuropharmacology Competitive Intelligence Tools for University-Based Technology Transfer Offices
Technology Transfer and Entrepreneurship (Discontinued) Protective Role of <i>Morus nigra</i> Leaf Extracts against Murine Infection with <i>Eimeria papillata</i>
Combinatorial Chemistry & High Throughput Screening Current Update on Synopsis of miRNA Dysregulation in Neurological Disorders
CNS & Neurological Disorders - Drug Targets